Loading…
Development of Apremilast Solid Dispersion Using TPGS and PVPVA with Enhanced Solubility and Bioavailability
Apremilast (APST) is an effective inhibitor of phosphodieasterase 4 (PDE4) which is the first oral drug for the treatment of adult patients with active psoriatic arthritis. However, Apremilast ’ s low solubility restricts its dissolution and bioavailability. In this study, APST solid dispersion with...
Saved in:
Published in: | AAPS PharmSciTech 2021-04, Vol.22 (4), p.142, Article 142 |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c347t-2c61165dc7a4ad6e933ee02c44863167277f768905483dda03873497374b2fd73 |
---|---|
cites | cdi_FETCH-LOGICAL-c347t-2c61165dc7a4ad6e933ee02c44863167277f768905483dda03873497374b2fd73 |
container_end_page | |
container_issue | 4 |
container_start_page | 142 |
container_title | AAPS PharmSciTech |
container_volume | 22 |
creator | Yang, Liuhong Wu, Penghui Xu, Jinchao Xie, Dihuan Wang, Zhongqing Wang, Qian Chen, Yong Li, Chuan Hua Zhang, Jiaxin Chen, Hangping Quan, Guilan |
description | Apremilast (APST) is an effective inhibitor of phosphodieasterase 4 (PDE4) which is the first oral drug for the treatment of adult patients with active psoriatic arthritis. However, Apremilast
’
s low solubility restricts its dissolution and bioavailability. In this study, APST solid dispersion with D-α-tocopherol polyethylene glycol 1000 succinate (TPGS) and Poly(1-vinylpyrrolidone-co-vinyl acetate) (PVPVA) was developed to improve the dissolution and bioavailability of APST by spray drying. A series of TPGS were synthesized to elucidate the effect of the ratio of monoester to diester on solubilizing capacity. X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), and Fourier transform infrared spectrophotometry (FT-IR) were used to characterize the solid dispersion, and the results showed that APST was amorphous in solid dispersion.
In vitro
dissolution study showed that the dissolution rate of solid dispersion in phosphate buffered saline (pH 6.8) was remarkably increased, reaching a release of 90% within 10 min. Moreover,
in vivo
pharmacokinetics study revealed that the bioavailability of solid dispersion in rats had significant improvement. In particular, its
C
max
and AUC
last
were nearly 22- and 12.9-fold greater as compared to APST form B, respectively. In conclusion, APST solid dispersion with TPGS and PVPVA is an alternative drug delivery system to improve the solubility and oral bioavailability of APST. |
doi_str_mv | 10.1208/s12249-021-02005-x |
format | article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1208_s12249_021_02005_x</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>33893566</sourcerecordid><originalsourceid>FETCH-LOGICAL-c347t-2c61165dc7a4ad6e933ee02c44863167277f768905483dda03873497374b2fd73</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EouXxAyyQfyBgexI7Xpa2FKRKVOpjG7mx07pKnShOS_v3pA0gVixGM5q590pzEHqg5IkyEj97ylgoA8JoU4REweECdWkEJJAS2OWfuYNuvN8QwoBKuEYdgFhCxHkX5QOzN3lRbo2rcZHhXlmZrc2Vr_G0yK3GA-tLU3lbODz31q3wbDKaYuU0niwmix7-tPUaD91audTok2e3tLmtj2fJiy3UXjVx7e4OXWUq9-b-u9-i-etw1n8Lxh-j935vHKQQijpgKaeURzoVKlSaGwlgDGFpGMYcKBdMiEzwWJIojEFrRSAWEEoBIlyyTAu4RazNTavC-8pkSVnZraqOCSXJCV3SoksadMkZXXJoTI-tqdwtt0b_Wn5YNQJoBb45uZWpkk2xq1zzyH-xX1hPeds</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Development of Apremilast Solid Dispersion Using TPGS and PVPVA with Enhanced Solubility and Bioavailability</title><source>Springer Link</source><creator>Yang, Liuhong ; Wu, Penghui ; Xu, Jinchao ; Xie, Dihuan ; Wang, Zhongqing ; Wang, Qian ; Chen, Yong ; Li, Chuan Hua ; Zhang, Jiaxin ; Chen, Hangping ; Quan, Guilan</creator><creatorcontrib>Yang, Liuhong ; Wu, Penghui ; Xu, Jinchao ; Xie, Dihuan ; Wang, Zhongqing ; Wang, Qian ; Chen, Yong ; Li, Chuan Hua ; Zhang, Jiaxin ; Chen, Hangping ; Quan, Guilan</creatorcontrib><description>Apremilast (APST) is an effective inhibitor of phosphodieasterase 4 (PDE4) which is the first oral drug for the treatment of adult patients with active psoriatic arthritis. However, Apremilast
’
s low solubility restricts its dissolution and bioavailability. In this study, APST solid dispersion with D-α-tocopherol polyethylene glycol 1000 succinate (TPGS) and Poly(1-vinylpyrrolidone-co-vinyl acetate) (PVPVA) was developed to improve the dissolution and bioavailability of APST by spray drying. A series of TPGS were synthesized to elucidate the effect of the ratio of monoester to diester on solubilizing capacity. X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), and Fourier transform infrared spectrophotometry (FT-IR) were used to characterize the solid dispersion, and the results showed that APST was amorphous in solid dispersion.
In vitro
dissolution study showed that the dissolution rate of solid dispersion in phosphate buffered saline (pH 6.8) was remarkably increased, reaching a release of 90% within 10 min. Moreover,
in vivo
pharmacokinetics study revealed that the bioavailability of solid dispersion in rats had significant improvement. In particular, its
C
max
and AUC
last
were nearly 22- and 12.9-fold greater as compared to APST form B, respectively. In conclusion, APST solid dispersion with TPGS and PVPVA is an alternative drug delivery system to improve the solubility and oral bioavailability of APST.</description><identifier>ISSN: 1530-9932</identifier><identifier>EISSN: 1530-9932</identifier><identifier>DOI: 10.1208/s12249-021-02005-x</identifier><identifier>PMID: 33893566</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Animals ; Biochemistry ; Biological Availability ; Biomedical and Life Sciences ; Biomedicine ; Biotechnology ; Calorimetry, Differential Scanning ; Dosage Forms ; Pharmacology/Toxicology ; Pharmacy ; Phosphodiesterase 4 Inhibitors - chemistry ; Phosphodiesterase 4 Inhibitors - pharmacokinetics ; Povidone - analogs & derivatives ; Povidone - chemistry ; Powder Diffraction ; Rats ; Research Article ; Solubility ; Spectroscopy, Fourier Transform Infrared ; Thalidomide - analogs & derivatives ; Thalidomide - chemistry ; Thalidomide - pharmacokinetics ; Vitamin E - chemistry</subject><ispartof>AAPS PharmSciTech, 2021-04, Vol.22 (4), p.142, Article 142</ispartof><rights>American Association of Pharmaceutical Scientists 2021. corrected publication 2021</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c347t-2c61165dc7a4ad6e933ee02c44863167277f768905483dda03873497374b2fd73</citedby><cites>FETCH-LOGICAL-c347t-2c61165dc7a4ad6e933ee02c44863167277f768905483dda03873497374b2fd73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33893566$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, Liuhong</creatorcontrib><creatorcontrib>Wu, Penghui</creatorcontrib><creatorcontrib>Xu, Jinchao</creatorcontrib><creatorcontrib>Xie, Dihuan</creatorcontrib><creatorcontrib>Wang, Zhongqing</creatorcontrib><creatorcontrib>Wang, Qian</creatorcontrib><creatorcontrib>Chen, Yong</creatorcontrib><creatorcontrib>Li, Chuan Hua</creatorcontrib><creatorcontrib>Zhang, Jiaxin</creatorcontrib><creatorcontrib>Chen, Hangping</creatorcontrib><creatorcontrib>Quan, Guilan</creatorcontrib><title>Development of Apremilast Solid Dispersion Using TPGS and PVPVA with Enhanced Solubility and Bioavailability</title><title>AAPS PharmSciTech</title><addtitle>AAPS PharmSciTech</addtitle><addtitle>AAPS PharmSciTech</addtitle><description>Apremilast (APST) is an effective inhibitor of phosphodieasterase 4 (PDE4) which is the first oral drug for the treatment of adult patients with active psoriatic arthritis. However, Apremilast
’
s low solubility restricts its dissolution and bioavailability. In this study, APST solid dispersion with D-α-tocopherol polyethylene glycol 1000 succinate (TPGS) and Poly(1-vinylpyrrolidone-co-vinyl acetate) (PVPVA) was developed to improve the dissolution and bioavailability of APST by spray drying. A series of TPGS were synthesized to elucidate the effect of the ratio of monoester to diester on solubilizing capacity. X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), and Fourier transform infrared spectrophotometry (FT-IR) were used to characterize the solid dispersion, and the results showed that APST was amorphous in solid dispersion.
In vitro
dissolution study showed that the dissolution rate of solid dispersion in phosphate buffered saline (pH 6.8) was remarkably increased, reaching a release of 90% within 10 min. Moreover,
in vivo
pharmacokinetics study revealed that the bioavailability of solid dispersion in rats had significant improvement. In particular, its
C
max
and AUC
last
were nearly 22- and 12.9-fold greater as compared to APST form B, respectively. In conclusion, APST solid dispersion with TPGS and PVPVA is an alternative drug delivery system to improve the solubility and oral bioavailability of APST.</description><subject>Animals</subject><subject>Biochemistry</subject><subject>Biological Availability</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Biotechnology</subject><subject>Calorimetry, Differential Scanning</subject><subject>Dosage Forms</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacy</subject><subject>Phosphodiesterase 4 Inhibitors - chemistry</subject><subject>Phosphodiesterase 4 Inhibitors - pharmacokinetics</subject><subject>Povidone - analogs & derivatives</subject><subject>Povidone - chemistry</subject><subject>Powder Diffraction</subject><subject>Rats</subject><subject>Research Article</subject><subject>Solubility</subject><subject>Spectroscopy, Fourier Transform Infrared</subject><subject>Thalidomide - analogs & derivatives</subject><subject>Thalidomide - chemistry</subject><subject>Thalidomide - pharmacokinetics</subject><subject>Vitamin E - chemistry</subject><issn>1530-9932</issn><issn>1530-9932</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kMtOwzAQRS0EouXxAyyQfyBgexI7Xpa2FKRKVOpjG7mx07pKnShOS_v3pA0gVixGM5q590pzEHqg5IkyEj97ylgoA8JoU4REweECdWkEJJAS2OWfuYNuvN8QwoBKuEYdgFhCxHkX5QOzN3lRbo2rcZHhXlmZrc2Vr_G0yK3GA-tLU3lbODz31q3wbDKaYuU0niwmix7-tPUaD91audTok2e3tLmtj2fJiy3UXjVx7e4OXWUq9-b-u9-i-etw1n8Lxh-j935vHKQQijpgKaeURzoVKlSaGwlgDGFpGMYcKBdMiEzwWJIojEFrRSAWEEoBIlyyTAu4RazNTavC-8pkSVnZraqOCSXJCV3SoksadMkZXXJoTI-tqdwtt0b_Wn5YNQJoBb45uZWpkk2xq1zzyH-xX1hPeds</recordid><startdate>20210423</startdate><enddate>20210423</enddate><creator>Yang, Liuhong</creator><creator>Wu, Penghui</creator><creator>Xu, Jinchao</creator><creator>Xie, Dihuan</creator><creator>Wang, Zhongqing</creator><creator>Wang, Qian</creator><creator>Chen, Yong</creator><creator>Li, Chuan Hua</creator><creator>Zhang, Jiaxin</creator><creator>Chen, Hangping</creator><creator>Quan, Guilan</creator><general>Springer International Publishing</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20210423</creationdate><title>Development of Apremilast Solid Dispersion Using TPGS and PVPVA with Enhanced Solubility and Bioavailability</title><author>Yang, Liuhong ; Wu, Penghui ; Xu, Jinchao ; Xie, Dihuan ; Wang, Zhongqing ; Wang, Qian ; Chen, Yong ; Li, Chuan Hua ; Zhang, Jiaxin ; Chen, Hangping ; Quan, Guilan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c347t-2c61165dc7a4ad6e933ee02c44863167277f768905483dda03873497374b2fd73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Animals</topic><topic>Biochemistry</topic><topic>Biological Availability</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Biotechnology</topic><topic>Calorimetry, Differential Scanning</topic><topic>Dosage Forms</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacy</topic><topic>Phosphodiesterase 4 Inhibitors - chemistry</topic><topic>Phosphodiesterase 4 Inhibitors - pharmacokinetics</topic><topic>Povidone - analogs & derivatives</topic><topic>Povidone - chemistry</topic><topic>Powder Diffraction</topic><topic>Rats</topic><topic>Research Article</topic><topic>Solubility</topic><topic>Spectroscopy, Fourier Transform Infrared</topic><topic>Thalidomide - analogs & derivatives</topic><topic>Thalidomide - chemistry</topic><topic>Thalidomide - pharmacokinetics</topic><topic>Vitamin E - chemistry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, Liuhong</creatorcontrib><creatorcontrib>Wu, Penghui</creatorcontrib><creatorcontrib>Xu, Jinchao</creatorcontrib><creatorcontrib>Xie, Dihuan</creatorcontrib><creatorcontrib>Wang, Zhongqing</creatorcontrib><creatorcontrib>Wang, Qian</creatorcontrib><creatorcontrib>Chen, Yong</creatorcontrib><creatorcontrib>Li, Chuan Hua</creatorcontrib><creatorcontrib>Zhang, Jiaxin</creatorcontrib><creatorcontrib>Chen, Hangping</creatorcontrib><creatorcontrib>Quan, Guilan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>AAPS PharmSciTech</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, Liuhong</au><au>Wu, Penghui</au><au>Xu, Jinchao</au><au>Xie, Dihuan</au><au>Wang, Zhongqing</au><au>Wang, Qian</au><au>Chen, Yong</au><au>Li, Chuan Hua</au><au>Zhang, Jiaxin</au><au>Chen, Hangping</au><au>Quan, Guilan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of Apremilast Solid Dispersion Using TPGS and PVPVA with Enhanced Solubility and Bioavailability</atitle><jtitle>AAPS PharmSciTech</jtitle><stitle>AAPS PharmSciTech</stitle><addtitle>AAPS PharmSciTech</addtitle><date>2021-04-23</date><risdate>2021</risdate><volume>22</volume><issue>4</issue><spage>142</spage><pages>142-</pages><artnum>142</artnum><issn>1530-9932</issn><eissn>1530-9932</eissn><abstract>Apremilast (APST) is an effective inhibitor of phosphodieasterase 4 (PDE4) which is the first oral drug for the treatment of adult patients with active psoriatic arthritis. However, Apremilast
’
s low solubility restricts its dissolution and bioavailability. In this study, APST solid dispersion with D-α-tocopherol polyethylene glycol 1000 succinate (TPGS) and Poly(1-vinylpyrrolidone-co-vinyl acetate) (PVPVA) was developed to improve the dissolution and bioavailability of APST by spray drying. A series of TPGS were synthesized to elucidate the effect of the ratio of monoester to diester on solubilizing capacity. X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), and Fourier transform infrared spectrophotometry (FT-IR) were used to characterize the solid dispersion, and the results showed that APST was amorphous in solid dispersion.
In vitro
dissolution study showed that the dissolution rate of solid dispersion in phosphate buffered saline (pH 6.8) was remarkably increased, reaching a release of 90% within 10 min. Moreover,
in vivo
pharmacokinetics study revealed that the bioavailability of solid dispersion in rats had significant improvement. In particular, its
C
max
and AUC
last
were nearly 22- and 12.9-fold greater as compared to APST form B, respectively. In conclusion, APST solid dispersion with TPGS and PVPVA is an alternative drug delivery system to improve the solubility and oral bioavailability of APST.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>33893566</pmid><doi>10.1208/s12249-021-02005-x</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1530-9932 |
ispartof | AAPS PharmSciTech, 2021-04, Vol.22 (4), p.142, Article 142 |
issn | 1530-9932 1530-9932 |
language | eng |
recordid | cdi_crossref_primary_10_1208_s12249_021_02005_x |
source | Springer Link |
subjects | Animals Biochemistry Biological Availability Biomedical and Life Sciences Biomedicine Biotechnology Calorimetry, Differential Scanning Dosage Forms Pharmacology/Toxicology Pharmacy Phosphodiesterase 4 Inhibitors - chemistry Phosphodiesterase 4 Inhibitors - pharmacokinetics Povidone - analogs & derivatives Povidone - chemistry Powder Diffraction Rats Research Article Solubility Spectroscopy, Fourier Transform Infrared Thalidomide - analogs & derivatives Thalidomide - chemistry Thalidomide - pharmacokinetics Vitamin E - chemistry |
title | Development of Apremilast Solid Dispersion Using TPGS and PVPVA with Enhanced Solubility and Bioavailability |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T00%3A55%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20Apremilast%20Solid%20Dispersion%20Using%20TPGS%20and%20PVPVA%20with%20Enhanced%20Solubility%20and%20Bioavailability&rft.jtitle=AAPS%20PharmSciTech&rft.au=Yang,%20Liuhong&rft.date=2021-04-23&rft.volume=22&rft.issue=4&rft.spage=142&rft.pages=142-&rft.artnum=142&rft.issn=1530-9932&rft.eissn=1530-9932&rft_id=info:doi/10.1208/s12249-021-02005-x&rft_dat=%3Cpubmed_cross%3E33893566%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c347t-2c61165dc7a4ad6e933ee02c44863167277f768905483dda03873497374b2fd73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/33893566&rfr_iscdi=true |